Quote:

---

after the meeting on mono with the fda.

---

I'm just putting myself in BP's shoes. In the past they were probably too far apart to agree on just combo.. BP is after mono, otherwise they would have shelled out big bucks before now for combo. If they are close to a deal, as NP is saying, BP must have move towards CYDY's side, I would imagine based on the mono data shared with them (which we have not seen yet). If all that is true, I would imagine BP is waiting to see what the FDA says and also to get the final mono pivotal trial details with primary & secondary endpoints. With the current data, they should be able to estimate the probability mono will succeed. There are over 500 patients now, so lots of data to extrapolate the outcome of the p3 mono trial.

all,imo.